Application of the HALF index obviates the need for liver biopsy in half of all patients with chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 6, 2011, Pages 987-995

  Lee, Hyun Jung ^a   Seo, Yeon Seok ^a   Kim, Dong Jin ^a   Kang, Hyun Seok ^a   An, Hyonggin ^a   Kim, Ji Hoon ^a   Cheong, Jae Youn ^b   Yim, Hyung Joon ^a   Yeon, Jong Eun ^a   Lee, Hong Sik ^a   Byun, Kwan Soo ^a   Cho, Sung Won ^b   Kim, Dong Joon ^c   Um, Soon Ho ^a   Kim, Chang Duck ^a   Ryu, Ho Sang ^a  

^a Korea University College of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

Author keywords

Apolipoprotein; Elastography; Fibrosis; Haptoglobin; Macroglobulin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HAPTOGLOBIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HYALURONIC ACID; TRIACYLGLYCEROL; VIRUS DNA;

ACCURACY; ADULT; ARTICLE; CONTROLLED STUDY; ELASTOGRAPHY; FEMALE; HALF INDEX; HEPATITIS B; HEPATITIS B VIRUS; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MODEL; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

EID: 79955908392     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06609.x     Document Type: Article

References (47)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
2. European Association for the Study of the L. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-42.
3. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36 (Suppl. 1): S152-60.
4. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N. Engl. J. Med. 2001; 344: 495-500.
5. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
6. Maharaj B, Maharaj RJ, Leary WP etal. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-5.
7. Regev A, Berho M, Jeffers LJ etal. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 2002; 97: 2614-18.
8. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.
9. Wai CT, Greenson JK, Fontana RJ etal. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
10. Forns X, Ampurdanes S, Llovet JM etal. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
11. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
12. Patel K, Gordon SC, Jacobson I etal. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J. Hepatol. 2004; 41: 935-42.
13. Myers RP, Tainturier MH, Ratziu V etal. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J. Hepatol. 2003; 39: 222-30.
14. Hui AY, Chan HL, Wong VW etal. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am. J. Gastroenterol. 2005; 100: 616-23.
15. Zeng MD, Lu LG, Mao YM etal. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005; 42: 1437-45.
16. Colletta C, Smirne C, Fabris C etal. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42: 838-45.
17. Sandrin L, Fourquet B, Hasquenoph JM etal. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol. 2003; 29: 1705-13.
18. Ganne-Carrie N, Ziol M, de Ledinghen V etal. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006; 44: 1511-17.
19. Ziol M, Handra-Luca A, Kettaneh A etal. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
20. Friedrich-Rust M, Ong MF, Martens S etal. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74.
21. Marcellin P, Ziol M, Bedossa P etal. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009; 29: 242-7.
22. Chan HL, Wong GL, Choi PC etal. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J. Viral Hepat. 2009; 16: 36-44.
23. Kim SU, Ahn SH, Park JY etal. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J. Clin. Gastroenterol. 2009; 43: 267-71.
24. Wang JH, Changchien CS, Hung CH etal. FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. J. Gastroenterol. 2009; 44: 439-46.
25. Fraquelli M, Rigamonti C, Casazza G etal. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-73.
26. Coco B, Oliveri F, Maina AM etal. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J. Viral Hepat. 2007; 14: 360-9.
27. Arena U, Vizzutti F, Corti G etal. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47: 380-4.
28. Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008; 47: 592-5.
29. Millonig G, Reimann FM, Friedrich S etal. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008; 48: 1718-23.
30. Castera L, Vergniol J, Foucher J etal. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
31. Cobbold JF, Crossey MM, Colman P etal. Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C. J. Viral Hepat. 2010; 17: 537-45.
32. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am. J. Surg. Pathol. 1995; 19: 1409-17.
33. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.
34. Bacq Y, Schillio Y, Brechot JF, De Muret A, Dubois F, Metman EH. Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol. Clin. Biol. 1993; 17: 364-9.
35. Louagie HK, Brouwer JT, Delanghe JR, De Buyzere ML, Leroux-Roels GG. Haptoglobin polymorphism and chronic hepatitis C. J. Hepatol. 1996; 25: 10-14.
36. Kanzler S, Lohse AW, Keil A etal. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am. J. Physiol. 1999; 276: G1059-G1068.
37. Tiggelman AM, Linthorst C, Boers W, Brand HS, Chamuleau RA. Transforming growth factor-beta-induced collagen synthesis by human liver myofibroblasts is inhibited by alpha2-macroglobulin. J. Hepatol. 1997; 26: 1220-8.
38. Tiggelman AM, Boers W, Moorman AF etal. Localization of alpha 2-macroglobulin protein and messenger RNA in rat liver fibrosis: evidence for the synthesis of alpha 2-macroglobulin within Schistosoma mansoni egg granulomas. Hepatology 1996; 23: 1260-7.
39. Meisse D, Renouf S, Husson A, Lavoinne A. Cell swelling increased the alpha2-macroglobulin gene expression in cultured rat hepatocytes. FEBS Lett. 1998; 422: 346-8.
40. Kawser CA, Iredale JP, Winwood PJ, Arthur MJ. Rat hepatic stellate cell expression of alpha2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin. Sci. 1998; 95: 179-86.
41. Poynard T, Aubert A, Bedossa P etal. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991; 100: 1397-402.
42. Pilette C, Rousselet MC, Bedossa P etal. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J. Hepatol. 1998; 28: 439-46.
43. Paradis V, Mathurin P, Ratziu V, Poynard T, Bedossa P. Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix. Hepatology 1996; 23: 1232-8.
44. Wai CT, Cheng CL, Wee A etal. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int. 2006; 26: 666-72.
45. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin. Chim. Acta 1997; 261: 159-65.
46. Castera L, Le Bail B, Roudot-Thoraval F etal. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J. Hepatol. 2009; 50: 59-68.
47. Poynard T, Halfon P, Castera L etal. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin. Chem. 2007; 53: 1615-22.